These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37705354)

  • 21. The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case.
    Oude Blenke E; Örnskov E; Schöneich C; Nilsson GA; Volkin DB; Mastrobattista E; Almarsson Ö; Crommelin DJA
    J Pharm Sci; 2023 Feb; 112(2):386-403. PubMed ID: 36351479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonclinical Safety Assessment of Lipid Nanoparticle-and Emulsion-Based Self-Amplifying mRNA Vaccines in Rats.
    Donahue DA; Ballesteros C; Maruggi G; Glover C; Ringenberg MA; Marquis M; Ben Abdeljelil N; Ashraf A; Rodriguez LA; Stokes AH
    Int J Toxicol; 2023; 42(1):37-49. PubMed ID: 36472205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics.
    Semple SC; Leone R; Barbosa CJ; Tam YK; Lin PJC
    Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Principles for designing an optimal mRNA lipid nanoparticle vaccine.
    Kon E; Elia U; Peer D
    Curr Opin Biotechnol; 2022 Feb; 73():329-336. PubMed ID: 34715546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. R848 Adjuvant Laden With Self-Assembled Nanoparticle-Based mRNA Vaccine Elicits Protective Immunity Against H5N1 in Mice.
    Zhuang X; Chen L; Yang S; Xia S; Xu Z; Zhang T; Zeng B; Yu T; Yu N; Wang W; Lu H; Tian M; Jin N
    Front Immunol; 2022; 13():836274. PubMed ID: 35711431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery.
    Maeki M; Uno S; Niwa A; Okada Y; Tokeshi M
    J Control Release; 2022 Apr; 344():80-96. PubMed ID: 35183654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nucleoside-Modified mRNA Vaccines Protect IFNAR
    Appelberg S; John L; Pardi N; Végvári Á; Bereczky S; Ahlén G; Monteil V; Abdurahman S; Mikaeloff F; Beattie M; Tam Y; Sällberg M; Neogi U; Weissman D; Mirazimi A
    J Virol; 2022 Feb; 96(3):e0156821. PubMed ID: 34817199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. mRNA vaccines for COVID-19 and diverse diseases.
    Hussain A; Yang H; Zhang M; Liu Q; Alotaibi G; Irfan M; He H; Chang J; Liang XJ; Weng Y; Huang Y
    J Control Release; 2022 May; 345():314-333. PubMed ID: 35331783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current Status and Future Perspectives on MRNA Drug Manufacturing.
    Webb C; Ip S; Bathula NV; Popova P; Soriano SKV; Ly HH; Eryilmaz B; Nguyen Huu VA; Broadhead R; Rabel M; Villamagna I; Abraham S; Raeesi V; Thomas A; Clarke S; Ramsay EC; Perrie Y; Blakney AK
    Mol Pharm; 2022 Apr; 19(4):1047-1058. PubMed ID: 35238565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nucleoside-Modified mRNA-Based Influenza Vaccines Circumvent Problems Associated with H3N2 Vaccine Strain Egg Adaptation.
    Gouma S; Furey C; Santos JJS; Parkhouse K; Weirick M; Muramatsu H; Pardi N; Fan SHY; Weissman D; Hensley SE
    J Virol; 2023 Jan; 97(1):e0172322. PubMed ID: 36533954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
    Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
    JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Future considerations for the mRNA-lipid nanoparticle vaccine platform.
    Igyártó BZ; Jacobsen S; Ndeupen S
    Curr Opin Virol; 2021 Jun; 48():65-72. PubMed ID: 33906124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced immunogenicity induced by mRNA vaccines with various lipid nanoparticles as carriers for SARS-CoV-2 infection.
    Zhang Y; Wang J; Xing H; Liu C; Zha W; Dong S; Jiang Y; Li X
    J Mater Chem B; 2023 Aug; 11(31):7454-7465. PubMed ID: 37448376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2.
    Mao S; Li S; Zhang Y; Long L; Peng J; Cao Y; Mao JZ; Qi X; Xin Q; San G; Ding J; Jiang J; Bai X; Wang Q; Xu P; Xia H; Lu L; Xie L; Kong D; Zhu S; Xu W
    Nano Today; 2023 Feb; 48():101730. PubMed ID: 36570700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An efficient approach for SARS-CoV-2 monoclonal antibody production via modified mRNA-LNP immunization.
    Hsu FF; Liang KH; Kumari M; Chen WY; Lin HT; Cheng CM; Tao MH; Wu HC
    Int J Pharm; 2022 Nov; 627():122256. PubMed ID: 36198358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates.
    Ripoll M; Bernard MC; Vaure C; Bazin E; Commandeur S; Perkov V; Lemdani K; Nicolaï MC; Bonifassi P; Kichler A; Frisch B; Haensler J
    Biomaterials; 2022 Jul; 286():121570. PubMed ID: 35576809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 T cells against a lethal viral infection.
    Knudson CJ; Alves-Peixoto P; Muramatsu H; Stotesbury C; Tang L; Lin PJC; Tam YK; Weissman D; Pardi N; Sigal LJ
    Mol Ther; 2021 Sep; 29(9):2769-2781. PubMed ID: 33992803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delivery and Expression of mRNA in the Secondary Lymphoid Organs Drive Immune Responses to Lipid Nanoparticle-mRNA Vaccines after Intramuscular Injection.
    Takanashi A; Pouton CW; Al-Wassiti H
    Mol Pharm; 2023 Aug; 20(8):3876-3885. PubMed ID: 37491979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enzyme-Catalyzed One-Step Synthesis of Ionizable Cationic Lipids for Lipid Nanoparticle-Based mRNA COVID-19 Vaccines.
    Li Z; Zhang XQ; Ho W; Li F; Gao M; Bai X; Xu X
    ACS Nano; 2022 Nov; 16(11):18936-18950. PubMed ID: 36269150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines.
    Szebeni J; Storm G; Ljubimova JY; Castells M; Phillips EJ; Turjeman K; Barenholz Y; Crommelin DJA; Dobrovolskaia MA
    Nat Nanotechnol; 2022 Apr; 17(4):337-346. PubMed ID: 35393599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.